What is DelSiTech?
DelSiTech operates as a specialized technology platform company centered on the development of long-acting formulations. By leveraging its proprietary Silica Matrix technology, the firm creates biodegradable drug delivery systems that are highly compatible with a wide array of therapeutic agents. This innovation is specifically engineered to address the challenges of metabolic diseases and pain management, offering a pathway to improved patient adherence through reduced dosing frequency. By positioning itself as a strategic partner to global biopharmaceutical entities, DelSiTech facilitates the advancement of next-generation therapeutics, effectively bridging the gap between complex drug chemistry and clinical application. The company's market position is defined by its ability to provide scalable, long-lasting treatment solutions that enhance therapeutic efficacy while simultaneously improving the quality of life for patients worldwide.
How much funding has DelSiTech raised?
DelSiTech has raised a total of $10.8M across 1 funding round:
Other Financing Round
$10.8M
Other Financing Round (2024): $10.8M with participation from Tolmar and DRW Venture Capital
Key Investors in DelSiTech
Tolmar
Tolmar Pharmaceuticals is a fully integrated pharmaceutical company focused on the innovative development, manufacturing, and commercialization of specialty pharmaceuticals across multiple therapeutic areas, including Urology.
DRW Venture Capital
DRW Venture Capital is a firm that focuses on investing in early-stage technology companies, providing both capital and strategic guidance to help startups scale their businesses.
What's next for DelSiTech?
With this recent infusion of capital, DelSiTech is well-positioned to accelerate its collaborative efforts with pharmaceutical partners and expand the reach of its Silica Matrix platform. The strategic focus will likely shift toward scaling manufacturing capabilities and advancing clinical pipelines that utilize its biodegradable delivery systems. As the company moves deeper into the enterprise-level phase of its lifecycle, the emphasis will remain on securing additional licensing agreements and validating the platform across a broader spectrum of therapeutic indications. By maintaining its commitment to innovation in drug delivery, DelSiTech is poised to solidify its role as an essential component of the modern pharmaceutical supply chain, driving long-term value for both its partners and the patients who rely on its transformative medical solutions.
See full DelSiTech company page
